Potential role of PKC inhibitors in the treatment of hematological malignancies.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current pharmaceutical design

• Publication date

  2008-06-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/138161208785294618PMID 18691117
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Curcumin: From ancient medicine to current clinical trials

  2008cited by this paper
• Targeting the protein kinase C family: are we there yet?

  2008cited by this paper
• Protein kinase inhibitors: structural insights into selectivity.

  2007cited by this paper
• Modulation of protein kinase C by curcumin; inhibition and activation switched by calcium ions

  2007cited by this paper
• Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562

  2007cited by this paper
• Protein kinase C and other diacylglycerol effectors in cancer

  2007cited by this paper
• Antiangiogenic therapy in malignant glioma: promise and challenge.

  2007cited by this paper
• Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.

  2007cited by this paper
• Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.

  2007cited by this paper
• Daphnane diterpene esters isolated from flower buds of Daphne genkwa induce apoptosis in human myelocytic HL-60 cells and suppress tumor growth in Lewis lung carcinoma (LLC)-inoculated mouse model.

  2007cited by this paper
• PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells.

  2007cited by this paper
• PKC inhibition is involved in trichosanthin-induced apoptosis in human chronic myeloid leukemia cell line K562.

  2007cited by this paper
• Molecular targets of curcumin.

  2007cited by this paper
• Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model

  2007cited by this paper
• JNK signalling: a possible target to prevent neurodegeneration.

  2007cited by this paper
• Subversion of protein kinase C alpha signaling in hematopoietic progenitor cells results in the generation of a B-cell chronic lymphocytic leukemia-like population in vivo.

  2006cited by this paper
• Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).

  2006cited by this paper
• Protein kinase C-beta as a therapeutic target in breast cancer.

  2006cited by this paper
• Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.

  2006cited by this paper
• PKCepsilon controls protection against TRAIL in erythroid progenitors.

  2006cited by this paper
• Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.

  2006cited by this paper
• Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines

  2006cited by this paper
• Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma

  2006cited by this paper
• The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology.

  2006cited by this paper
• Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma

  2005cited by this paper
• Decursin and PDBu: two PKC activators distinctively acting in the megakaryocytic differentiation of K562 human erythroleukemia cells.

  2005cited by this paper
• Involvement of PKC and ROS in the cytotoxic mechanism of anti-leukemic decursin and its derivatives and their structure-activity relationship in human K562 erythroleukemia and U937 myeloleukemia cells.

  2005cited by this paper
• Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

  2005cited by this paper
• Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms

  2005cited by this paper
• The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.

  2005cited by this paper
• FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies

  2005cited by this paper
• Protein Kinase C-dependent Protein Kinase D Activation Modulates ERK Signal Pathway and Endothelial Cell Proliferation by Vascular Endothelial Growth Factor*

  2005cited by this paper
• Toward the development of new medicinal leads with selectivity for protein kinase C isozymes.

  2005cited by this paper
• Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

  2005cited by this paper
• PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC.

  2005cited by this paper
• N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells.

  2005cited by this paper
• PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia.

  2005cited by this paper
• Wnts induce migration and invasion of myeloma plasma cells.

  2005cited by this paper
• LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice

  2004cited by this paper
• TRAIL regulates normal erythroid maturation through an ERK-dependent pathway.

  2004cited by this paper
• Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy.

  2004cited by this paper
• The enigmatic protein kinase Cδ: complex roles in cell proliferation and survival

  2004cited by this paper
• Indolactam and benzolactam compounds as new medicinal leads with binding selectivity for C1 domains of protein kinase C isozymes.

  2004cited by this paper
• Biological Properties of Curcumin-Cellular and Molecular Mechanisms of Action

  2004cited by this paper
• Penta-acetyl geniposide-induced C6 glioma cell apoptosis was associated with the activation of protein kinase C-delta.

  2004cited by this paper
• Advances in chemotherapy for chronic lymphocytic leukemia.

  2004cited by this paper
• Curcumin (Diferuloylmethane) Inhibits Constitutive and IL-6-Inducible STAT3 Phosphorylation in Human Multiple Myeloma Cells 1

  2003cited by this paper
• PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

  2003cited by this paper
• STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1.

  2003cited by this paper
• Rapid and selective apoptosis in human leukemic cells induced by Aplidine through a Fas/CD95- and mitochondrial-mediated mechanism.

  2003cited by this paper
• Protein kinase C‐delta is commonly expressed in multiple myeloma cells and its downregulation by rottlerin causes apoptosis

  2003cited by this paper
• Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis.

  2003cited by this paper
• Anti-tumor activities of decursinol angelate and decursin fromAngelica gigas

  2003cited by this paper
• Cancer chemoprevention with dietary phytochemicals

  2003cited by this paper
• Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.

  2002cited by this paper
• Characterization of protein kinase C β isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization

  2002cited by this paper
• Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway.

  2002cited by this paper
• Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

  2002cited by this paper
• Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.

  2002cited by this paper
• Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine

  2002cited by this paper
• Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas?

  2002cited by this paper
• Aplidin™ induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C δ

  2002cited by this paper
• Differential expression of protein kinase C isoenzymes related to high nitric oxide synthase activity in a T lymphoma cell line.

  2002cited by this paper
• The clinical development of the bryostatins

  2002cited by this paper
• Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.

  2002cited by this paper
• Protein kinase C inhibitors as novel anticancer drugs

  2001cited by this paper
• Distinct PKC isozymes regulate bufalin-induced differentiation and apoptosis in human monocytic cells.

  2001cited by this paper
• Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis.

  2001cited by this paper
• Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies.

  2001cited by this paper
• Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts.

  2001cited by this paper
• Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.

  2001cited by this paper
• Protein kinase C delta and eta isoenzymes control the shedding of the interleukin 6 receptor alpha in myeloma cells.

  2001cited by this paper
• Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

  2000cited by this paper
• PKC-delta is an apoptotic lamin kinase.

  2000cited by this paper
• Regulation of Phospholipid Scramblase Activity during Apoptosis and Cell Activation by Protein Kinase Cδ*

  2000cited by this paper
• Lineage-restricted expression of protein kinase C isoforms in hematopoiesis.

  1999cited by this paper
• Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays

  1999cited by this paper
• Protein kinase ctheta cooperates with calcineurin to induce Fas ligand expression during activation-induced T cell death.

  1999cited by this paper
• Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis.

  1999cited by this paper
• VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells

  1999cited by this paper
• In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells.

  1998cited by this paper
• A Functional Role for Mitochondrial Protein Kinase Cα in Bcl2 Phosphorylation and Suppression of Apoptosis*

  1998cited by this paper
• Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

  1998cited by this paper
• Inactivation of DNA-Dependent Protein Kinase by Protein Kinase Cδ: Implications for Apoptosis

  1998cited by this paper
• Activation of protein kinase C delta by the c-Abl tyrosine kinase in response to ionizing radiation.

  1998cited by this paper
• Ginsenoside Rh2 and Rh3 induce differentiation of HL-60 cells into granulocytes: modulation of protein kinase C isoforms during differentiation by ginsenoside Rh2.

  1998cited by this paper
• Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells.

  1998cited by this paper
• Regulation of protein kinase C.

  1997cited by this paper
• Cytochrome c-dependent and -independent Induction of Apoptosis in Multiple Myeloma Cells*

  1997cited by this paper
• Thrombopoietin enhances the alpha IIb beta 3-dependent adhesion of megakaryocytic cells to fibrinogen or fibronectin through PI 3 kinase.

  1997cited by this paper
• Lineage commitment of transformed haematopoietic progenitors is determined by the level of PKC activity.

  1996cited by this paper
• Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.

  1996cited by this paper
• Nuclear translocation of protein kinase C-alpha and -zeta isoforms in HL-60 cells induced to differentiate along the granulocytic lineage by all-trans retinoic acid.

  1996cited by this paper
• Changes of nuclear protein kinase C activity and isotype composition in PC12 cell proliferation and differentiation.

  1996cited by this paper
• Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth.

  1996cited by this paper
• Proteolytic Activation of Protein Kinase C δ by an ICE/CED 3-like Protease Induces Characteristics of Apoptosis

  1996cited by this paper
• Proteolytic activation of protein kinase C delta by an ICE‐like protease in apoptotic cells.

  1995cited by this paper
• Protein kinase C and lipid signaling for sustained cellular responses

  1995cited by this paper
• Protein kinase C--a question of specificity.

  1994cited by this paper
• Specific role for protein kinase C beta in cell differentiation.

  1994cited by this paper

• p62 Binding to Protein Kinase C Regulates HIV-1 gp120 V3 Loop Induced Microglial Inflammation

  2024cites this paper
• Repurposing Drugs in Small Animal Oncology

  2022cites this paper
• The function of SUMOylation and its crucial roles in the development of neurological diseases

  2021cites this paper
• The Effects of Phosphatidylserine (PS) Expression on HL 60, and the Efficacy of the Role of Doxorubicin (DOX) on HL60

  2019cites this paper
• The biology of protein kinase C.

  2012cites this paper
• Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase

  2011cites this paper
• Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma

  2011cites this paper
• Phorbol ester phorbol‐12‐myristate‐13‐acetate induces epithelial to mesenchymal transition in human prostate cancer ARCaPE cells

  2010cites this paper
• Protein kinase C - possible therapeutic target to treat cardiovascular diseases.

  2010cites this paper
• Cell cycle as a target of antineoplastic drugs.

  2010cites this paper
• Development of agents that modulate protein-protein interactions in membranes.

  2010cites this paper
• Receptor tyrosine kinase inhibitors as potent weapons in war against cancers.

  2009cites this paper
• Evolving strategies in manipulating VEGF/VEGFR signaling for the promotion of angiogenesis in ischemic muscle.

  2009cites this paper
• The discovery of antiangiogenic molecules: a historical review.

  2009cites this paper
• Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions.

  2009cites this paper
• Editorial: Innovative therapeutical approaches for hematological malignancies based on molecular targeted therapies.

  2008cites this paper